A2抗原异源腺病毒/Leish-Tec疫苗接种策略:内脏利什曼病小鼠模型研究
本研究在内脏利什曼病小鼠模型中评估基于A2抗原的腺病毒载体(AdA2)与重组蛋白(LeishTec)同源及异源接种方案的免疫原性与降低寄生虫负荷能力。120只雌性BALB/c小鼠分寄生虫负荷组和免疫应答组,各含六种方案。异源AdA2+LT方案显著降低骨髓寄生虫负荷(多数动物检测不到虫体DNA),并诱导强T细胞免疫,优于其他方案。
要点
- 同源LT方案诱导最高抗A2抗体滴度。
- 异源AdA2+LT方案使多数动物骨髓虫体DNA检测不到。
- AdA2+LT诱导TNF-α和IFN-γ阳性CD4+及CD8+ T细胞应答增强。
核心结论
- 异源AdA2+LT接种策略在小鼠模型中优于其他方案,是有前景的内脏利什曼病疫苗候选方案。
研究设计与样本
- 研究将120只雌性BALB/c小鼠分为寄生虫负荷组和免疫应答组,每组六种方案:Ad、AdA2、LT、AdA2+LT、LT+AdA2、PBS。
- 寄生虫负荷组免疫后30天以婴儿利什曼原虫攻击,用定量PCR检测脾和骨髓虫负荷;免疫应答组用流式细胞术分析脾细胞。
主要发现
- 同源LT方案诱导最高的抗A2抗体滴度。
- 异源AdA2+LT方案显著降低骨髓寄生虫负荷,多数动物骨髓中检测不到虫体DNA。
- AdA2+LT方案诱导强细胞免疫,包括TNF-α和IFN-γ阳性CD4+ T细胞增加、中央和效应记忆亚群扩增及抗原刺激后CD8+ T细胞产生TNF-α和IFN-γ增强。
临床怎么用
- 该异源接种策略支持进一步开发犬用内脏利什曼病疫苗以阻断人兽共患传播。
局限性
- 研究仅在小鼠模型中进行,尚未在犬或人群验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Zoonotic visceral leishmaniasis caused by Leishmania infantum is the most severe clinical form of leishmaniasis and remains endemic in multiple regions, where it can be fatal if untreated. Domestic dogs act as the main urban reservoirs, sustaining zoonotic transmission. This study evaluated the immunogenicity and ability to reduce parasite burden of homologous and heterologous vaccination regimens based on the Leishmania amastigote A2 antigen administered as a recombinant adenovirus vector (AdA2) or a purified recombinant protein (LeishTec vaccine - LT) in a murine model. A total of 120 female BALB/c mice were allocated into two experimental arms: Parasite Burden (PB) and Immune Response (IR), each comprising six protocols: Ad (adenovirus-β-galactosidase), AdA2 (adenovirus-A2), LT (LeishTec), AdA2+LT, LT+AdA2, and PBS. Anti-A2 antibodies were quantified by indirect ELISA. In the PB arm, mice were challenged with Leishmania infantum 30 days after immunization, and parasite burden in spleen and bone marrow was determined by quantitative PCR. In the IR arm, splenocytes were analyzed by flow cytometry to assess cellular immune responses. The homologous LT regimen induced the highest anti-A2 antibody titers. Notably, the heterologous AdA2+LT protocol was associated with a marked reduction in bone marrow parasite burden, with undetectable parasite DNA in most animals in this organ. This regimen also induced robust cellular immunity, characterized by increased TNF-α- and IFN-γ-producing CD4+ T cells, expansion of central and effector memory subsets, and enhanced TNF-α and IFN-γ production by CD8+ T lymphocytes after antigen stimulation. Overall, the AdA2+LT heterologous strategy outperformed the other regimens and represents a promising vaccination approach against visceral leishmaniasis.
引用
- Amado-Gomes AC, Clímaco MC, Cirilo TM, et al. Heterologous adenovirus A2/Leish-Tec® vaccination strategy in a murine model of visceral leishmaniasis: Potential canine vaccine with enhanced protection and potent T-cell immunity. Vaccine. 2026. PMID: 42727397. doi:10.1016/j.vaccine.2026.129105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。